Moderna Disables Comments On X Post Announcing New Covid Shot Amid Backlash
This post was republished with permission from Zero Hedge
Moderna shares rose in premarket trading after the company announced FDA approval of its new lower-dose Covid-19 vaccine, mNEXSPIKE, for adults aged 65 and older, as well as individuals 12–64 with underlying health conditions. However, the approval sparked backlash on X, with many questioning the Trump administration and Health Secretary Robert F. Kennedy Jr.’s “MAHA” (Make America Healthy Again) agenda.
Moderna said in a Saturday morning X post that the mNEXSPIKE (mRNA-1283) vaccine should be available in the U.S. in time for the 2025-26 respiratory virus season, which starts later this year.
“The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19,” CEO Stéphane Bancel stated in a press release.
Bancel noted, “COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA’s timely review and thank the entire Moderna team for their hard work and continued commitment to public health.”
Last month, the FDA announced that Covid vaccines would not be offered this fall to healthy children and adults. At the same time, the Trump administration stated that any new Covid vaccines must undergo clinical trials using an inert placebo—such as saline—rather than being tested against existing approved vaccines.
Moderna’s X post was met with heavy backlash, as many users voiced outrage over the FDA’s approval, under Health Secretary RFK Jr., of yet another round of Covid vaccines.
Moderna’s social media team disabled comments on the post. Bottom line: people are furious:
Despite the backlash on X, Wall Street analysts welcomed Moderna’s new Covid vaccine, viewing it as a potential catalyst to lift the battered stock off its 52-week lows (list courtsey of Bloomberg):
Barclays, Gena Wang (equal weight)
Leerink Partners, Mani Foroohar (underperform)
William Blair, Myles R. Minter (market perform)
Shares were up more than 2% in premarket trading.
All you need to know: Moderna disabled comments on its X post—clearly unable to handle the wave of criticism over its new product.
As for Trump’s MAHA agenda, X sentiment isn’t thrilled—many are voicing frustration with RFK Jr.’s FDA and its latest vaccine approval. Why not approve alternative treatments?
Your support is crucial in helping us defeat mass censorship. Please consider donating via Locals or check out our unique merch. Follow us on X @ModernityNews.
Source link